Melanoma Matters14 Okt 2024

Ep 34: CHOPIN & SCANDIUM trials for Uveal Melanoma

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel discuss a couple of liver-directed trials in metastatic uveal melanoma. They focus on the CHOPIN and SCANDIUM trials, the combination of liver-directed therapies with systemic treatments, and the safety and efficacy of these approaches. The conversation highlights the innovative efforts of European investigators and the need for adaptive trial designs in rare diseases.

Keywords

melanoma, uveal melanoma, SCANDIUM, CHOPIN, liver directed therapy, systemic therapy, checkpoint inhibitors, cancer research, clinical trials, treatment options

Takeaways

We have limited treatment options for metastatic uveal melanoma.

Combining liver-directed therapy with systemic therapy is being explored.

Future trials are needed to understand optimal sequencing of therapies.

Adaptive trial designs may be challenging in rare cancers.

European investigators are leading innovative trials in this field.

The importance of collaboration in cancer research is emphasized.

Sound Bites

"We have a couple of approved agents."

"Is it safe to combine these therapies?"

"The IHP treatment had a superior response rate."

Chapters

00:00 Introduction and Icebreaker Question

01:52 Background and Objectives of the Studies

04:17 Results and Conclusions of the Scandium, Scandium-2, and Chopin Studies

06:28 Feasibility of Adaptive Trials for Rare Cancers

08:52 The Importance of International Collaboration in Uveal Melanoma Research

09:48 Closing Remarks and Future Directions

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Sep 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Aug 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Aug 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Aug 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Jul 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Jul 35min

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Jun 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Jun 1h 4min